UCI 趙 Chao Family Comprehensive Cancer Center



Hepatobiliary and Pancreas Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Open to Accrual | Low Accruing | Pending Activation/Suspended

Hepatocellular

LOCOREGIONAL + SYSTEMIC

NRG GI012
Atezo/bev, Durva/treme, Nivo/ipi w/wo SBRT

Coord: B. Nguyen
Accrual: 2/5

FIRST LINE

UCI 22-106
STAT3 + Atezolizumab and Bevacizumab
(Slot request required)
Coord: H. Nguyen
Accrual: 11/15

UCI 26-54
PF-08634404 (PD1/VEGF mAb) + Ipilimumab
Accrual: 0/11
Coord: S. Zamora
Accrual: 0/17

UCI 22-211
MED1572 (IgG1 mAb) ± Bev
Suspended for additional cohort review
SUSPENDED
Coord: B. Nguyen
Accrual: 4/8

SECOND LINE/THIRD LINE

UCI 16-94
TATE + Nivolumab

Coord: S. Zamora
Accrual: 41/48

UCI 23-215
AZD5851 (GPC3 Autologous CAR-T)
Central testing for GPC3/GPC3
Suspended until Q3 2026
SUSPENDED
Coord: TBD
Accrual: 0/5

UCI 24-09
RYZ801 (GPC3 radiotherapeutic)

Accrual: 1/10
Coord: H. Nguyen

ETCTN 10703
Sapanisertib (mTOR kinase inhibitor) + Cabozantinib
B-catenin positivity during Phase 2

Coord: S. Duong
Accrual: 1/3

UCI 25-218
Visugromab (IgG4 GDF-15)
Nivolumab and Lenvatinib, or Lenvatinib/double placebo

Accrual: 1/10
Coord: S. Zamora

Open to Accrual | Low Accruing | Pending Activation/Suspended

Biliary Tract Carcinoma

SYSTEMIC + OPERATIVE

ETCTN 10608
Gemcitabine + Cisplatin + Durva
Neo/Adjuvant for **high-risk resectable ICC**
SUSPENDED
Coord: H. Nguyen
Accrual: 2/3

FIRST LINE

UCI 22-211 (GEMINI)
MED1572 (IgG1 mAb) or AZD2936 (TIGIT) ± gemcitabine and cisplatin
Slot request
SUSPENDED
Coord: B. Nguyen
Accrual: 4/8

UCI 21-10
TJ033721 (CLDN18 Inhibitor) + Gem/Cis/Durva
Slot request
Coord: B. Nguyen
Accrual: 39/50

UCI 25-204 (Artemide
Rilvegostomig or Durvalumab with Gemcitabine/Cisplatin

Coord: H. Nguyen
Accrual: 1/10

SECOND LINE+

UCI 25-137
Nanvuranlat (LAT1 inhibitor) vs. Physician choice chemotherapy

Accrual 0/10
Coord: S. Duong

UCI 26-60
ASP546C in Participants with **CLDN 18.2 (cohort 4)**
PENDING ACTIVATION
Coord: TBD
Accrual 0/10

Open to Accrual | Low Accruing | Pending Activation/Suspended

Pancreatic

FIRST LINE LA/METASTATIC

UCI 23-200
AZD0901 (ADC) with
NAL-IRI or Gemcitabine-**CLDN 18.2**
Slot request
SUSPENDED
Coord: S. Duong
Accrual: 5/10

UCI 22-51
ASP2138 (CLDN18.2 BiTe) with
FOLFIRINOX-**CLDN 18.2**
Slot request
CLOSED TO ACCRUAL
Coord: S. Duong
Accrual: 35/35

UCI 21-10
TJ033721 (CLDN18 Inhibitor) +
gemcitabine + nab-paclitaxel-
CLDN 18.2
Slot request
Coord: B. Nguyen
Accrual: 39/50

UCI 25-216
Relacorilant w/gem/nab-pcalitaxel
mPDAC diagnosed w/in 6 weeks
Coord: H. Nguyen
Accrual: 0/10

UCI 25-229
ASP3082 w/mFOLFIRINOX or
NALIRIFOX- **KRAS G12D**
Coord: S. Zamora
Accrual: 0/8

UCI 26-21
INCB161734 w/ mFOLFIRINOX or
Gem/Nab-Paclitaxel (DAWN-303)-
KRAS G12D
Coord: R. Gaytan
Accrual: 1/10

UCI 26-98
ANO31905 for Injection in Combo
with Chemotherapy - **CLDN 18.2**
NEW
Coord: TBD
Accrual:. 0/12

SECOND LINE

UCI 24-105
Pitavastatin + Gemcitabine/Nab-paclitaxel
Stable disease after 2 months of treatment w/gem/nab-paclitaxel
Coord: S. Duong
Accrual: 2/18

UCI 25-228
ODM-212 (Hippo pathway)
PDAC – Gemcitabine/Nab-paclitaxel
Accrual: 1/10
Coord: H. Nguyen

UCI 26-60
ASP546C in Participants with
CLDN 18.2 (cohort 3)
PENDING ACTIVATION
Coord: TBD
Accrual 0/10

FIRST LINE SUPPORTIVE CARE

UCI 25-120
Ponsegromab (GD15 blocker) vs.
placebo for cachexia
Accrual: 2/40
Coord: S. Zamora

Open to Accrual | Low Accruing | Pending Activation/Suspended

BORDERLINE/ LOCALLY ADVANCED

ETCTN-10366
M3814 (Peposertib) + radiation
SUSPENDED
Coord: S. Duong
Accrual: 13/18

UCI 23-134
Padeliporfin vascular targeted photodynamic (VTP) therapy
Pancreatic head/uncinate

Coord: H. Nguyen
Accrual: 8/15

NRG-GI011
Dose escalated radiation

Coord: B. Nguyen
Accrual: 0/10

UCI 26-100
Perioperative Fostamatinib with Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
Pending Activation
Coord: TBD
Accrual: 0/8

RECURRENT/EXHAUSTIVE

UCI 24-08
SPEDOX -6 (Protein encapsulated doxorubicin)
KRAS Mutation

Coord: B. Nguyen
Accrual: 9/67

UCI 24-113
BMS-986482 (Treg inducer)

PI: Dr. Chow
Coord: S. Duong
Accrual: 5/10

Review Biomarker Based Solid Tumors Pages 6 and 7

ETCTN 10522
CA4948 + gemcitabine + nab-paclitaxel
SUSPENDED
Coord: B. Nguyen
Accrual: 5/10

Pancreatic

Neuroendocrine Tumors

SECOND LINE+

ETCTN 10479
Lu-177 + Sunitinib

Well or moderately differentiated PNET
Up to one line of systemic therapy not including somatostatin
Slot request required

Coord: H. Nguyen
Accrual: 2/3

Biomarker Based Solid Tumors

Mutation based studies allowing Pancreatic, liver, and biliary cancers + other solid tumors

Open to Accrual | Low Accruing | Pending Activation/Suspended

CLAUDIN 18.2

UCI 22-51
ASP2138 (CLDN18.2 BiTe) with FOLFIRINOX-**CLDN 18.2**
Slot request
CLOSED TO ACCRUAL
Coord: S. Duong
Accrual: 35/35

UCI 21-10
TJ033721 (CLDN18 Inhibitor) + gemcitabine + nab-paclitaxel-**CLDN 18.2**
Slot request
Coord: B. Nguyen
Accrual: 39/50

UCI 26-60
ASP546C in Participants with **CLDN 18.2 (cohort 3/4)**
PENDING ACTIVATION
Coord: TBD
Accrual 0/10

ALK

UCI 21-241
NVL- 655 (ALK inhibitor)
Accrual: 20/25
PI: Dr. Nagasaka
Coord: TBD

MTAP

UCI 24-197
TNG456 (PRMT5 inhibitor)

MTAP NGS/IHC **local** testing
Accrual: 1/5
PI: Dr. Park
Coord: TBD

SMARCA2

UCI 25-194
Drug: PLX-61639 (SMARCA2 degrader)

Inclusive of all solid tumors with SMARC4 mutations
Accrual: 0/5
PI: Dr. Villaflor
Coord: TBD

HER2

ETCTN-10495
(+ Neratinib)
Accrual: 2/7
PI: Dr. Dayyani
Coord: TBD

KRAS

UCI 25-163
BBO-11818
Inclusive of all solid tumors with **KRAS G12C, G12D, G12V**
Accrual: 0/5
PI: Dr. Arter
Coord: K. Patel

UCI 26-21
INCB161734 w/ mFOLFIRINOX or Gem/Nab-Paclitaxel (DAWN-303)- **KRAS G12D**

Coord: R. Gaytan
Accrual: 1/10

UCI 25-229
ASP3082 w/mFOLFIRINOX or NALIRIFOX- **KRAS G12D**

Coord: B. Nguyen
Accrual: 0/8

Advanced Solid Tumors

Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

Open to Accrual | Low Accruing | Pending Activation/Suspended

UCI 22-26
CB-03-10 (Androgen and glucocorticoid antagonist)
SUSPENDED
Accrual: 11/12
Coord: B. Nguyen

UCI 24-142
VET3-TGI (IL-12 and TGF-B inhibiting vaccine) ± Pembrolizumab
Intra-tumoral or IV
Accrual: 3/4
PI: Dr. Uchio
Coord: TBD

UCI 25-16
ODM-212 (Hippo pathway)

Reach out to coordinator for selected tumor types
Accrual: 14/20
Coord: TBD
PI: Dr. Dayyani

UCI 25-228
ODM-212 (Hippo pathway)

PDAC – Gemcitabine/Nab-paclitaxel
Accrual: 1/10
Coord: H. Nguyen

ETCTN 10579
Drug: ZEN-3694 (BET Inhibitor) + capecitabine
Inclusive of all solid tumors in dose escalation
Accrual: 3/4
PI: Dr. Lee

UCI 25-190 (STOPGAP-B)
Intraperitoneal Paclitaxel + Systemic Therapy

Accrual: 8/40
Coord: R. Gaytan
PI: Dr. Senthil

Open to Accrual | Low Accruing | Pending Activation/Suspended

Correlative and Supportive

BLOOD COLLECTION

UCI 21-124
ctDNA collection during HBP workup
PI: Dr. Abi
Coord: TBD
Accrual: 17/19

UCI 23-10/PRECEDE
(Blood collection for early detection of pancreatic cancer)
PI: Dr. Valerin
Coord: TBD
Accrual: 1/20

UCI 22-55
Blood and biomarker collection for early detection and diagnosis of DNA Deficient Hereditary Cancers

PI: Dr. Valerin and Dr. Pannunzio
Coord: TBD
Accrual: 37/50

BEHAVIORAL

UCI 25-177
Refinement and usability of e-support for pancreatic cancer patients
Coord: TBD
PI: Dr. Jacqueline Kim